drugset

drugset / Trial / NCT00688883

Fludara (Oral) Phase II Study for Indolent Lymphoma

NCT00688883 ↗

Phase 2 Completed 52 enrolled Genzyme, a Sanofi Company

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To assess the antitumor effect and safety of Fludara in patients with indolent lymphoma.

Timeline

Start: 2003-02
Primary completion: 2004-08
Completion: 2004-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Fludarabine	Small molecule	40 mg/m2	Oral

Indications